Embera NeuroTherapeutics

Embera wins $11M NIDA grant for cocaine addiction treatment EMB-001

Wednesday, July 27, 2016

Embera NeuroTherapeutics, a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, has received an $11.1 million, three-year grant from the National Institute on Drug Abuse (NIDA), part of the NIH. The grant will support continued clinical development of EMB-001 for the treatment of cocaine addiction, which is clinically termed “cocaine use disorder.”

[Read More]